COVID-19 convalescent plasma (PCC) has emerged as a possible remedy for COVID-19. However, knowledge and recommendations from the meta-analysis are limited. A team led by the AABB Committee on Clinical Transfusion Medicine reviewed published studies to establish guidelines. Live systematic reviews of RCTs assessing CCP from 1 January 2019 to 26 January 2022 included 33 RCTs assessing 21,916 participants.
Based on the data, the AABB recommends that patients outside the hospital with the highest threat of disease progression get a CCP transfusion in addition to the same previous care. The AABB also discourages CCP transfusion in hospitalized patients with moderate or severe disease. however, he states that CCP transfusion deserves to be added to the same old popular care for those who do not have anti-SARS-2 antibodies detected on admission and for those with pre-existing immunosuppression. The AABB discourages prophylactic transfusion of CCP for other uninfected individuals who have been in close contact with someone with COVID-19. The AABB summarized its findings in intelligent clinical practice: CCP is most effective when transfused with higher neutralizing titers some time after symptom onset.
The researchers summarized the effects of the GRADE (Grading of Recommendations Assessment, Development and Evaluation) method. Recommendations were made assuming that patients would place great importance on avoiding the dangers of disease progression, morbidity and mortality similar to COVID-19. Therefore, where knowledge suggested that SPC transfusions had limited harm and that there were advantages to CCP, the panel was ready to make recommendations for CCP.
Please indicate the appropriate maximum category to facilitate the processing of your application
Thank you for taking the time to provide your feedback to the editors.
Your opinion is for us. However, we do not guarantee individual responses due to the large volume of messages.